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aBstract
Background and Aims: the principle of complete mesocolic excision for colon cancer 
has been introduced to improve oncologic outcome. however, this approach is scantily 
discussed for laparoscopic surgery and there is a lack of randomized trials. this study 
examined oncologic and clinical outcome after laparoscopic wide mesocolic excision and 
central vascular ligation for colon cancer.
Material and Methods: this is a review of prospectively gathered data from a single-
institution colorectal cancer database. this study was conducted in the central hospital 
of central finland. from January 2003 to december 2011, 222 patients underwent 
laparoscopic colonic resections with wide mesocolic excision and central vascular ligation 
in the multimodal setting. the main measures of outcome were cancer recurrence and 
survival, with early recovery, 30d-mortality and morbidity, reoperation, readmission, and 
late complications as secondary outcomes.
Results: the median follow-up was 5.5 (interquartile range (iQr) = 3.7–8.0) years. the 
5-year overall survival for all 222 patients was 80.2% and disease-specific survival was 
87.5%, and for those 210 r0-patients with stage i–iii disease, 83.9% and 91.3%, respectively. 
the 5-year disease-free survival was 85.8%: stage i was 94.7%, stage ii was 90.8%, and stage 
iii was 75.6% (p = 0.004). increasing lymph node ratio significantly decreased the 5-year 
disease-free survival. conversion rate to open surgery was 12.2%. thirty-day mortality 
was 1.3% and morbidity, 19.7%. Median postoperative hospital stay was 5 (iQr = 3–7) 
days.
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Conclusion: Laparoscopic wide mesocolic excision and central vascular ligation for colon 
cancer resulted in good long-term oncologic outcome. randomized trials are needed to 
show that laparoscopic complete mesocolic excision technique would become the standard 
of care for the carcinoma of the colon.
Key words: Laparoscopy; colon cancer; multimodal treatment; short- and long-term outcome
InTRODUCTIOn
Mesocolic excision together with locoregional lymph 
node removal has long been applied in colon cancer 
surgery. However, the extent of mesocolic dissection 
has not been well standardized in contrast to rectal 
cancer surgery where total mesorectal excision (TME) 
along the embryological planes has significantly 
improved survival (1). Moreover, previous studies 
have shown that there is variability in the quality of 
colon surgery, and the long-term oncologic outcome 
after resection for colon cancer may not have been 
optimal (2, 3).
Earlier studies have indicated that the oncologic 
outcome of open colon cancer surgery is directly 
related to the extent and completeness of mesenteric 
excision (4–7). Based on these observations, the princi-
ple of complete mesocolic excision (CME) for colon 
cancer has been recently re-emphasized (2, 4, 5, 8). The 
concept of CME is based on wide mesenteric excision 
according to the embryological planes to remove mes-
enteric lymph nodes, central vascular ligation to 
remove central lymph nodes, and resection of an ade-
quate length of bowel to remove pericolic lymph 
nodes (8).
Several randomized trials comparing laparoscopic 
versus open resection for colon cancer have shown 
that the laparoscopic method can provide an equiva-
lent oncologic outcome, a similar rate of complica-
tions, and a faster short-term recovery than the open 
method (9–12). A recent consensus statement agrees 
that CME is equally well suited for open as laparo-
scopic surgery (8). However, CME technique is scant-
ily discussed for laparoscopic surgery and there is a 
lack of randomized trials (8, 13, 14). The aim of this 
study was to assess the impact of laparoscopic wide 
mesocolic excision and central vascular ligation for 
colon cancer on clinical and oncologic outcome in the 
multimodal setting.
MATERIALS AnD METHODS
From 2003 to 2011, 222 patients with colon cancer 
admitted at the Central Hospital of Central Finland 
underwent a laparoscopic segmental colectomy 
using wide mesenteric excision and central vascular 
ligation. Preoperative staging was done by colo- 
noscopy and thoracoabdominal computed tomogra-
phy (CT). Previous major abdominal surgery, body 
mass index >35 kg/m2 and patients with signifi- 
cant cardiac/pulmonary comorbidity in whom a 
prolonged laparoscopic surgery would have been 
potentially harmful were relative contraindications 
to laparoscopy. Excluded were patients undergoing 
open surgery, those with carcinoma occurring in the 
setting of inflammatory bowel disease, or emergency 
situation such as obstruction and perforation as well 
as those with radiological evidence of T4-disease 
necessitating a major en-bloc resection of adjacent 
organs. The main measures of outcome were cancer 
recurrence and survival, with early recovery, 
30d-mortality and morbidity, reoperation, readmis-
sion, and late complications as secondary outcomes. 
Data were extracted from the local colorectal cancer 
database. Hospital records were also carefully 
reviewed. The study was approved by the ethics 
committee of the hospital.
SURGICAL TREATMEnT
Perioperative care included the assessment and opti-
mization of medical risk factors, selective use of 
mechanical bowel preparation, thromboprophylaxis 
with low molecular weight heparin and elastic stock-
ings, standard anesthesia with epidural analgesia, 
avoidance of hypothermia, and increased oxygen con-
centrations. nasogastric tubes were removed at the 
operation theater.
Laparoscopic surgery for colon cancer using the 4- 
or 5- trocar technique and mediolateral dissection 
along Toldt’s fascia was implemented in 2003. The 
Erlangen principles, first described by Hohenberger 
et  al. in 2003 (4) and later re-emphasized by 
Hohenberger et al. (5), West et al. (2, 3), and an interna-
tional consensus conference (8), were adopted in 2003 
in order to standardize surgery. Laparoscopic surgery 
was initially done by three senior surgeons having 
experience in laparoscopic colorectal surgery for 
benign diseases since 1993.
Right colon cancers were managed with medial to 
lateral mobilization along the right side of the supe-
rior mesenteric vein and central ligation of ileocolic 
artery and right colic artery, when present, and preser-
vation of the trunk of middle colic artery. Carcinomas 
of the hepatic flexure and right transverse colon were 
managed by extended right hemicolectomy and cen-
tral transection of ileocolic, right colic artery, when 
present, and the trunk of middle colic artery. 
Gastroepiploic lymph nodes and lymph nodes over 
the pancreatic head were not routinely dissected. 
Tumors of the middle transverse colon were treated 
either with extended right hemicolectomy or with 
transverse colon resection and central ligation of mid-
dle colic artery.
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Carcinomas of the left transverse colon or splenic 
flexure were treated with extended left hemicolec-
tomy and central ligation of the middle colic artery 
and inferior mesenteric artery. Division of the inferior 
mesenteric vein and transverse mesocolon were done 
at the lower edge of the pancreas.
Carcinomas of the descending colon were managed 
with left hemicolectomy and central ligation of infe-
rior mesenteric artery with distal limit in the upper 
third of rectum and division of inferior mesenteric 
vein at the lower border of the pancreas. Sigmoid and 
rectosigmoid tumors were treated with sigmoid resec-
tions with central ligation of inferior mesenteric artery 
and bowel transection in the upper rectum. Because 
lymphogenous spread of colon carcinoma to the peri-
colic nodes is at most for a distance of 10 cm, the aim 
was to achieve proximal and distal margins of 10 cm 
from the tumor. A 5-cm rule was accepted, if the anas-
tomosis was made in the upper rectum. Ileocolic anas-
tomoses were made side-to-side using linear staplers 
and left-side anastomoses were double-stapled using 
linear and circular staplers. The operation was consid-
ered non-curative, if the patient had synchronous dis-
tant metastases and/or the resection margins were 
involved.
Postoperative feeding consisted of free intake of 
liquids on the first postoperative day, semisolids on 
the second day, and normal food thereafter. Patients 
were discharged when they were able to have nor-
mal diet, pain free on oral analgesics, capable to han-
dle their stoma, and mobilized. Conversion to open 
surgery was defined as a necessity to interrupt the 
laparosopic procedure and to proceed using conven-
tional technique. Postoperative early complications 
were classified according to the Dindo–Clavien clas-
sification (15). Long-term morbidity was defined as 
surgical morbidity occurring more than 30 days after 
surgery.
nEOADJUVAnT AnD ADJUVAnT TREATMEnT
Adjuvant postoperative chemotherapy consisting of 
5-fluorouracil (FU) and oral folinic acid, oral capecit-
abine, or the FOLFOX-regimen since 2005 for 6 months 
were prescribed to medically fit patients having stage 
III tumors or high-risk stage II disease. Patients having 
two or more liver metastases during the follow-up 
usually received perioperative chemotherapy with 
FOLFOX-regimen and biologicals.
PATHOLOGICAL EXAMInATIOn
Tumors were staged by staff pathologists according to 
the sixth edition of the Union for International Cancer 
Control (UICC/TnM) categories (16). Pathological 
assessment of the quality of the surgical specimen 
according to the principles first described by West 
et al. in 2008 (2, 3) was not done in this study. Lymph 
node (Ln) ratio was formed by defining the propor-
tion of metastatic lymph nodes from total number of 
Lns examined. Intervals were determined using the 
following cut-off values: Ln ratio I <10%, Ln ratio II 
10%–25%, and Ln ratio III > 25%.
FOLLOW-UP
Follow-up examination included carcinoembryonic 
antigen (CEA) every 6 months, annual clinical exami-
nation, ultrasonographic investigation of the liver, and 
chest radiograph as well as colonoscopy 4–5 years 
postoperatively. Further characterization of metasta-
ses was done using CT, magnetic resonance imaging 
(MRI), and CT-positron emission tomography (PET) 
examination since 2005. Surgery for recurrent disease 
was performed when appropriate. Locoregional recur-
rence was defined as a recurrent tumor at the anasto-
motic site or locoregionally in the abdomen, and 
diagnosed by CT, MRI, and endoscopy whether newly 
diagnosed distant metastases were absent or present. 
The causes of death were obtained from the national 
Cause of Death Registry.
STATISTICAL AnALySIS
Results are given as mean (SD) or median (interquar-
tile range, IQR). The Kaplan–Meier method was used 
to calculate survival and the differences between 
groups were compared with the log-rank test. 
Survival times were calculated from the date of sur-
gery until the time of death or the end of follow-up. 
Analysis of prognostic factors for disease-free sur-
vival (DFS) was done using univariate and multivar-
iate Cox proportional hazards regression model in 
stage I–III patients. Only variables with p < 0.20 at 
univariate analysis were entered in the multivariate 
analysis. All statistical tests were two-sided. A p less 
than 0.05 was considered significant. STATA 
(StatCorp 2009. Stata release 11, Statistical Software. 
College Station, TX: StataCorp LP) was used for sta-
tistical analysis.
RESULTS
Baseline clinical and tumor characteristics are shown 
in Tables 1 and 2. Conversion to open surgery was 
done in 27 patients (12.2%). The reasons were unex-
pected invasion of adjacent organs/tumor adhesions 
in 10, bowel adhesions in five, otherwise difficult anat-
omy/obesity in nine, intraoperative complications in 
two, and technical problems in one. Multivisceral 
resections were performed in 10 patients having unex-
pected finding of adjacent organ invasion. Short-term 
surgical outcome is shown in Table 3.
LOnG-TERM OnCOLOGIC OUTCOME
no patients were lost to follow-up. Five of the 12 stage 
IV patients underwent secondary liver resection (n = 4) 
or cervical lymphadenectomy (n = 1) for metastases. 
During the median follow-up of 5.5 (IQR 3.7–8.0) 
years, 32 of the 210 R0-patients (15.2%) with stage I–III 
tumors had recurrent disease (locoregional and dis-
tant, nine (4.3%), distant only 23 (11.0%)), and 12 of 
them (37.5%) underwent 20 salvage operations for 
recurrent disease: liver resection, six; liver thermoab-
lation, one; lung resection, eight; colon/small bowel 
resection, three; resection of ovary and bladder wall, 
one; resection of port site recurrence, one. Three other 
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patients with a metachronous colon cancer underwent 
a second colon resection.
The 5-year overall survival (OS) for all 222 patients 
was 80.2% (95% CI: 74.0–85.1) and disease-specific 
survival (DSS) was 87.5% (81.9–91.4), and for those 
210 R0-patients with stage I–III disease, 83.9% (77.7–
88.4) and 91.3% (86.0–94.6), respectively. The 5-year 
DSS was 97.3% (82.3–99.6) for stage I, 95.6% (86.8–98.6) 
for stage II, and 83.5% (71.9–90.1) for stage III, p = 0.02. 
The 5-year DFS was 85.8% (80.1–90.0): stage I 94.7% 
(80.6–98.7), stage II 90.8% (82.3–95.3), and stage III 
75.6% (64.0–83.9), p = 0.004 (Fig. 1). Increasing Ln ratio 
significantly decreased the 5-year DFS rate: 91.7% 
(85.8–95.2) for Ln ratio <10%, 77.1% (59.5–87.9) for Ln 
ratio 10%–25%, and 56.1% (30.5–75.5) for Ln ratio 
>25%, p < 0.001 (Fig. 2). Tumor site (right-sided 86.3% 
(78.2–91.5) vs. left-sided 85.3% (76.0–91.2, p = 0.69) had 
no impact on the 5-year DFS rate.
Univariate and multivariate analyses for DFS were 
performed in 210 patients with stage I–III disease. 
Of all patient-, tumor-, and treatment-related factors, 
UICC stage (p = 0.007), Ln ratio (p < 0.001), and adju-
vant chemotherapy (p = 0.003) were prognostic factors 
for DFS in univariate analysis (Table 4). In multivariate 
analysis, Ln ratio (p = 0.04) was the only independent 
prognostic factor for DFS, whereas other variables 
included in the multivariate model failed to achieve 
statistical significance.
LOnG-TERM COMPLICATIOnS
After excluding the 30-day postoperative mortality, 
late complications occurred in 13 of the 219 patients 
(5.9%) and subsequent late reoperation were per-
formed in nine patients: five ventral hernias were cor-
rected as well as two port site hernias. Two anastomotic 
strictures corrected with resection and re-anastomosis, 
and four patients with bowel obstruction were man-
aged conservatively.
DISCUSSIOn
Previous studies have shown that open resections with 
CME and central vascular ligation translate into low 
local recurrence rates and good overall survival (2, 5), 
and significantly improve DFS compared with conven-
tional open colon resection (17). Laparoscopic CME 
surgery has been mainly reported for right-sided colon 
cancers (13, 14), and there is a lack of randomized 
trials. Our results show that after laparoscopic surgery 
for colon cancer according to the Erlangen principles 
TABLE 1
Baseline characteristics and multimodal treatment.
N = 222
Age, mean (SD), years 68.4 (11.0)
Male gender, n (%) 125 (56.1)
Body mass index (BMI), kg/m2, mean (SD) 25.4 (3.1)
ASA score III–IV, n (%) 105 (47.1)
Comorbid conditions, n (patients) (%)a
 Cardiovascular 67 (29.7)
 Pulmonary 28 (12.6)
 Hypertension 92 (41.4)
 Diabetes 27 (12.2)
 Liver disease 1 (0.5)
 Kidney disease 4 (1.8)
 Other (minor) 65 (29.3)
Type of surgery, n (%)
 Right hemicolectomy 89 (40.1)
 Extended right hemicolectomy 24 (10.8)
 Transverse colon resection 1 (0.5)
 Left hemicolectomy 20 (9.0)
 Extended left hemicolectomy 9 (4.1)
 Sigmoid resection 74 (33.3)
 Subtotal/total colectomy, proctocolectomyb 5 (2.3)
 Multivisceral resection, n (patients) (%)a 10 (4.5)
 Duodenal/jejunal resection 2/3 (2.2)
 Abdominal wall 1 (0.4)
 Salpingo-oophorectomy 2 (0.9)
 Bladder resection 2 (0.9)
 Liver resection 1 (0.4)
 Adrenalectomy 1 (0.4)
Postoperative chemotherapy, n (%)
 Adjuvant chemotherapy stage II 12/92 (13.0)
 Adjuvant chemotherapy stage III 70/80 (87.5)
 Chemotherapy for metastatic disease 11/12 (91.7)
SD: standard deviation; ASA: American Society of 
Anesthesiologists.
a Figures in the columns are not additive because some patients had 
more than one comorbid condition or resection of other organs.
b One patient with carcinoma of the ascending and sigmoid colon, 
other patients with an additional large adenoma not removable by 
colonoscopy or numerous adenomas.
TABLE 2
Tumor characteristics and surgical specimen.
N = 222
Tumor site, n (%)a
 Caecum/ascending colon 92 (41.4)
 Hepatic flexure 21 (9.5)
 Transverse colon 8 (3.6)
 Splenic flexure 5 (2.3)
 Descending colon 7 (3.2)
 Sigmoid/rectosigmoid colon 89 (40.1)
Tumor morphology
 Adenocarcinoma 206 (92.8)
 Mucinous adenocarcinoma 14 (6.3)
 Signet ring cell carcinoma 2 (0.9)
pTumor stage, n (%)
 I 38 (17.1)
 II 92 (41.4)
 III 80 (36.0)
 IV 12 (5.4)
Tumor diameter, median (IQR), cmb 4.5 (3.5–5.6)
Proximal resection margin, median (IQR), cmb 14.8 (10.0–22.0)
Distal resection margin, median (IQR), cmb 8.0 (5.0–11.0)
no. of lymph nodes studied, median (IQR) 14.0 (9.0–19.0)
Lymph node ratio, n of patients, (%)
 Ln ratio 0% 134 (60.4)
 Ln ratio 0.1%–9.9% 25 (11.3)
 Ln ratio 10%–25% 38 (17.1)
 Ln ratio >25% 25 (11.3)
IQR: interquartile range; Ln: lymph node.
aOne patient had carcinoma of the ascending and sigmoid colon.
bFormalin-fixed specimens.
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(4, 5), medial to lateral mobilization of the colon along 
Toldt’s fascia and central vascular ligation within mul-
timodal treatment strategy and an attempt to do sal-
vage surgery for metastatic disease when feasible, the 
5-year overall, disease-specific, and DFS rates as well 
as locoregional recurrence rates were comparable with 
those reported after open surgery by the Erlangen and 
Danish groups (5, 17). The extent of nodal involvement 
was the main prognostic factor for DFS after poten-
tially curative (R0) resection. Overall, the laparoscopic 
surgery could be done with a relatively high rate of 
technical success, low postoperative mortality, overall 
short-term morbidity, reoperation and readmission 
rates, and short hospital stay.
The concept of CME has a similar rationale to that 
of TME for rectal cancer including central vascular 
ligation and removal of lymphovascular pedicle of the 
tumor-bearing colon segment within complete mesen-
teric envelope. Although the anatomy of the mesoco-
lon and surgical planes has been extensively discussed 
for laparoscopic surgery as well as the rationale 
of CME (2, 3, 5, 8, 18), several studies have yielded 
conflicting results concerning the validity of wide 
mesenteric excision and lymphadenectomy with 
respect to survival despite a greater number of Ln 
removed (19). In contrast, previous studies have 
shown that improving the plane of mesocolic dissec-
tion improved survival, especially in stage III patients 
(2, 17). Therefore, a good quality mesocolic excision 
along the anatomic planes to obtain intact mesocolic 
resection planes without rupture and cancer cell seed-
ing might be equally important than the extent of mes-
ocolic excision. In our study, the extent of mesocolic 
resection, when judged by the median length of proxi-
mal and distal resection margins as well as the num-
ber of Lns studied, can be considered adequate. 
Higher Ln counts have been reported by other studies 
TABLE 3
Operative data and short-term recovery.
N = 222
Duration of surgery, median (IQR), min 120 (105–142)
Operative blood loss, median (IQR), mL 50.0 (10.0–100)
Conversion rate, n (%) 27 (12.1)
Oral intake of liquids >1000 mL, median (IQR), d 1 (1–1)
Intake of solids, median (IQR), d 2 (2–3)
Passage of flatus, median (IQR), d 2 (1–3)
Hospital stay, median (IQR), d 5 (4–7)
30-day mortality, n (%) 3 (1.3)
30-day morbidity, n (%)a 44 (19.7)
 Cardiac 8 (3.6)
 Pulmonary 6 (2.7)
 Renal 0 (0)
 Anastomotic leakb 21 (9.5)
 Abdominal abscess 2 (0.9)
 Wound infection 5 (2.2)
 Wound dehiscentia 3 (1.3)
 Postoperative bleeding 2 (0.9)
 Adynamic ileus 8 (3.6)
 Urinary tract infection 4 (1.8)
 Urinary retention 2 (0.9)
 Other 5 (2.2)
Dindo–Clavien classification, severe morbidity, n (%)
 Grade IIIb 8 (3.6)
 Grade IV 11 (4.9)
 Grade V 3 (1.3)
Early (30d) reoperations, n (%) 17 (7.7)
Readmission rate (30d, n (%)c 12/219 (5.5)
IQR: interquartile range.
a Figures in the column are not additive, because some patients had 
more than one complication.
bConservative treatment with antibiotics in four patients.
cPostoperative deaths excluded (n = 3).
Fig. 1. Disease-free survival by tumor stage I–III.
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(5, 17), possibly reflecting tumor- and patient-related 
factors as well as the quality of the pathologic exami-
nation. The quality of mesocolic resection planes was 
not examined here because the quality criteria for the 
assessment of the surgical specimen were first intro-
duced in 2008 (2).
The nodal positivity rate for colorectal cancer con-
sistently approximates 40% across a wide range of 
studies internationally (20) as shown also here (39.6%). 
Our study also demonstrated that an increasing Ln 
ratio was associated with the development of distant 
metastases and significantly reduced DFS. However, 
patients with negative Lns probably do not benefit 
from the CME technique. Previous studies have indi-
cated that high Ln ratio (21) and the presence of meta-
static apical Lns in some patients with stage III tumors 
may reflect a more aggressive biological behavior and 
worse survival (19, 20). In agreement with that, a 
recent meta-analysis demonstrated that performing a 
high tie arterial ligation in colonic cancer to achieve 
apical Ln clearance did not improve survival (22). 
Subpyloric and gastroepiploic Lns are not generally 
considered part of the colonic lymphatic system, but 
may harbor cancer cells in 1.1%–3.8% and 4% of cases, 
respectively.8 According to recent consensus guide-
lines, the excision of these Ln stations in cases of obvi-
ous tumor spread is warranted (8). This was not 
routinely done in our cohort of patients. Further stud-
ies are needed to assess the clinical relevance of 
extended lymphadenectomy.
Postoperative 30-day mortality rate (1.3%) in this 
study compares well with the reported range of 
2%–5% from other European countries (5, 17). Also, 
the 30-day morbidity was in line with other reports. 
Anastomotic leakage is the most significant compli-
cation after colon resection. The reported incidence of 
symptomatic leakage in previous studies is com-
monly around 3%–10% (23–25) and being 9.4% here, 
was the main reason for laparotomy. Because most 
leaks occurred in left-sided anastomosis, one of the 
reasons may be a high tie, central vascular ligation 
causing hypoperfusion of the proximal colon limb 
(23, 24). The overall 30-day reoperation rate (7.7%) 
and 30-day readmission rate (5.5%) compare well 
with the figures reported from other centers. 
Late complications were rare. Although long-term 
hernia rates are expected to be infrequent following 
Fig. 2. Disease-free survival by lymph node ratio in patients with stage I–III cancer.
TABLE 4
Reduced univariate Cox regression model analysis of disease-free 
survival: UICC stage I–III patients (n = 210).
Hazard ratios (95%CI) p
UICC stage p = 0.007*
 I 1
 II 2.19 (0.50–9.98)
 III 5.65 (1.32–24.18)
Ln ratio p < 0.001*
 <10% 1
 10%–25% 3.07 (1.33–7.10)
 >25% 6.14 (2.65–14.20)
Adjuvant chemotherapy p = 0.003
 no 1
 yes 2.96 (1.45–6.07)
UICC: Union for International Cancer Control; Ln: lymph node.
*P for linearity.
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laparoscopic colon cancer surgery, five ventral hernias 
in patients who underwent conversion to open sur-
gery were corrected surgically as well as two trocar 
site hernias. Two patients with anastomotic strictures 
underwent a late re-anastomosis.
A major challenge with this study and other similar 
studies is its single center nature and the lack of rand-
omization and pathologic quality grading of the surgi-
cal specimens, first introduced by West et al. in 2008 
(2). The learning curve and evolving laparoscopic 
experience may have played a role as well. However, 
laparoscopic colon surgery was done according to 
modern laparoscopic principles and technical aspects 
described by Hohenberger et  al. already in 2003 (4). 
Our survival figures also compare well with those 
reported in the literature (5, 17), particularly in stage 
III patients, indicating that the quality of surgery has 
been reasonably good.
COnCLUSIOn
Laparoscopic wide mesocolic excision and central vas-
cular ligation, today known as CME surgery, is a feasi-
ble technique for colon cancer surgery and results in 
good long-term oncologic outcome. Level 1 evidence 
for wide mesocolic excision and central vascular liga-
tion is missing. Improving the plane of mesenteric dis-
section might be equally important. Randomized 
trials are needed to show that laparoscopic CME sur-
gery would become the standard of care for the carci-
noma of the colon in the future.
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